BTA 0.00% 57.0¢ biota holdings limited

hospital superbugs

  1. 2,038 Posts.
    lightbulb Created with Sketch. 51
    Hospital Superbugs now in focus.....Dec28 Telegraph UK.....Disinfectants can encourage deadly superbugs, research finds....The bug is an important cause of hospital-acquired infections, which kill thousands each year.

    With the above creating news Biota could well be on a winner with either/or Prolysis (which is based at Oxford in England)/MaxThera (which is based in Boston in the US)
    Prolysis has two projects developing antibiotics to manage hospital superbugs.
    MaxThera also had two programs targeting drug-resistant bacterial infections, including those commonly known as superbugs or golden staph.
    Prolysis and MaxThera might appear similar, but each had a potential product in its own right.
    Biota expects to invest $25m over the next three years developing key programs acquired from Prolysis, thereby extending its current anti-viral portfolio to include a new pipeline of early stage anti-bacterial programs.
    Biota also intends to accelerate the development of MaxThera's lead program and invest up to $US15m over the next three to five years.

    Let's hope the above investments prove up new income streams for Biota.
    GL all holders and Wishing all a Happy and prosperous New Year.
 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.